Riskpilot← Back to searchSign inGet full accessLINK Medical Research AB
ABActiveOrg 5568946569Slottsgränd 2 AAll other professional, scientific and technical activities n.e.c. · NACE 7499Est. 201261 employees
Revenue 2024
SEK 116,9M
-20% vs 2023
EBITDA margin
-4.1%
-240% vs 2023
Equity ratio
9.2%
Financial strength
Net profit 2024
SEK -4,8M
-261% vs 2023
| Revenue | SEK 116,9M | -20% |
| EBITDA | SEK -4,7M | -240% |
| Net profit | SEK -4,8M | -261% |
| Total assets | SEK 54,5M | -11% |
| Equity | SEK 5M | -49% |
| Employees | 61 | — |
Legal name
LINK Medical Research AB
Org number
5568946569
Legal form
Aktiebolag
NACE code
7499 · All other professional, scientific and technical activities n.e.c.
Founded
30 maj 2012
Share capital
SEK 50 000
Employees
61 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva konsultverksamhet inom klinisk läkemedelsprövning och därmed förenlig verksamhet.
Address
Slottsgränd 2 A
Phone
+46184303100
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 127 566 | 165 350 | 155 082 | 147 038 | 116 900 |
| Staff expenses | — | — | — | — | −65 167 |
| EBITDA | 4 336 | 7 094 | 7 613 | 3 381 | −4 743 |
| Depreciation & amort. | −0 | −84 | −248 | −366 | −366 |
| EBIT | 4 336 | 7 010 | 7 365 | 3 015 | −5 109 |
| Net financials | −675 | −4 820 | 1 825 | 851 | 237 |
| Profit before tax | 5 307 | 2 191 | 9 198 | 3 866 | −4 940 |
| Tax | −1 162 | −1 601 | −1 935 | −866 | −115 |
| Net profit | 4 145 | 590 | 7 263 | 3 000 | −4 825 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 59 397 | 59 781 | 46 511 | 61 425 | 54 526 |
| Equity | 7 043 | 1 632 | 7 896 | 9 848 | 5 023 |
| Long-term debt | 0 | 2 700 | 0 | 0 | 1 264 |
| Short-term debt | 52 354 | 55 448 | 37 434 | 49 081 | 47 666 |
| Total debt | 52 354 | 58 148 | 37 434 | 49 081 | 48 930 |
EBITDA margin
-4.1%
This company
15.8%
Market median
-126% vs market
20202024
Equity ratio
9.2%
This company
38.2%
Market median
-76% vs market
20202024
Return on equity
-96.1%
This company
18.4%
Market median
-622% vs market
20202024
Net profit margin
-4.1%
This company
8.1%
Market median
-151% vs market
20202024
Asset turnover
2.14×
This company
1.12×
Market median
+91% vs market
20202024
Debt / equity
9.86×
This company
0.62×
Market median
-1490% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
JH Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2025 |
CA Chief Executive Officer | Chief Executive Officer | 2025 |
AP Chief Auditor | Chief Auditor | 2021 |
| Former (9) | ||
CK Authorized Recipient of Service | Authorized Recipient of Service | 2020 – 2020 |
TI Chief Executive Officer | Chief Executive Officer | 2020 – 2022 |
SM Authorized Recipient of Service | Authorized Recipient of Service | 2020 – 2022 |
ÅB Authorized Recipient of Service | Authorized Recipient of Service | 2022 – 2025 |
LL Chief Auditor | Chief Auditor | 2020 – 2021 |
MA Authorized Recipient of Service | Authorized Recipient of Service | 2022 – 2023 |
TS Chief Executive Officer | Chief Executive Officer | 2020 – 2021 |
SL Chief Executive Officer | Chief Executive Officer | 2022 – 2025 |
OG Chief Executive Officer | Chief Executive Officer | 2022 – 2023 |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
LINK MEDICAL AS
LINK Medical Research AB (this company)Board members of LINK Medical Research AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Camilla Kristina Rigmor Beijer | Authorized Recipient of Service | 0 companies |
| Tom Ivar Horvei | Chief Executive Officer | 0 companies |
| Sara Maria Pohl | Authorized Recipient of Service | 0 companies |
| Åsa Birgit Margaretha Lindkvist | Authorized Recipient of Service | 0 companies |
| Jan Helge Golmen | Deputy Chief Executive Officer | 0 companies |
| Carl Anders Göransson | Chief Executive Officer | 0 companies |
| Lars Ludwig Holmgren | Chief Auditor | 0 companies |
| Anders Patrik Nygard | Chief Auditor | 0 companies |
| Mia Alice Ann-Marie Grandin | Authorized Recipient of Service | 0 companies |
| Torkild Stenbock | Chief Executive Officer | 0 companies |
| Sissel Lønning Andresen | Chief Executive Officer | 0 companies |
| Ola Gudmundsen | Chief Executive Officer | 0 companies |